Genomics plc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Genomics plc - overview
Established
2014
Location
Oxford, -, UK
Primary Industry
Biotechnology
About
Based in Oxford, the UK and founded in 2014 by CEO Professor Peter Donnelly, Professor Gil McVean, Dr. Gerton Lunter, and Dr. Chris Spencer, Genomics plc is a healthcare company that uses large-genetic information to develop precision healthcare tools and engage in drug discovery for individuals as well as for health systems. In 2018, Vertex Pharmaceuticals Inc.
, collaborated with Genomic plc for three years, extendable to five years, to use human genetics to improve the discovery of drugs for precision medicines. In 2020, Genomics plc incorporated its US subsidiary, Genomic Inc. In 2021, Genomics plc raised USD 30 million in venture funding co-led by returning investors F-Prime Capital and Foresite Capital, with participation from other returning investors. In 2021, Genomics plc launched a pilot study to predict patients’ risk of heart disease using an integrated polygenic and clinical risk tool.
As of 2021, the company staffs over 100 employees across three offices in the UK and the US. The company’s algorithms and databases link minute variations across human genomes to changes in thousands of biological measurements and disease outcomes. Genomics also delivers insights for healthcare systems, clinicians, and pharmaceutical companies. The company’s products are offered through its precision health division and therapeutics division.
Genomics plc measures an individual’s genetic code and provides preventive solutions for genetic risks and other non-genetic factors including risk for cancers, cardiovascular diseases, autoimmune disorders, and diabetes. The company provides a polygenic risk score as a summary of genetic predisposition to a particular health condition for over 30 diseases. Genomics’s therapeutics division is engaged in the discovery and development of new medicines. The company plans to utilize the proceeds from venture funding to develop a patient-centric, population health framework that enables a more proactive, and personalized approach to healthcare.
Current Investors
Tanarra Capital, Longview Innovation , Invesco Perpetual
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Pharmaceutical Research & Development, Medical Software, Analytics & Performance Software
Website
www.genomicsplc.com
Verticals
Artificial Intelligence
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Genomics plc - timeline of key events
Genomics plc - financials
| Fiscal Year Ended | Jan 31, 2016 | Jan 31, 2017 | Jan 31, 2018 | Jan 31, 2019 | Jan 31, 2020 | Jan 31, 2021 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 81,810 | 111,071 | 522,204 | 2,825,870 | 2,409,633 | 2,406,441 | 2,542,268 | - | - | - |
| % Revenue Growth (YoY) | - | 35.8% | 370.2% | 441.1% | (14.7%) | (0.1%) | - | - | - | - |
| EBITDA (USD) | (1,996,424) | (3,272,254) | (3,354,295) | (2,917,643) | (6,444,757) | (12,347,315) | (14,023,172) | - | - | - |
| Operating Income (USD) | (2,035,233) | (3,538,039) | (3,652,353) | (3,225,570) | (6,856,285) | (12,882,286) | (14,511,601) | - | - | - |
| Operating Margin | (2487.8%) | (3185.4%) | (699.4%) | (114.1%) | (284.5%) | (535.3%) | (570.8%) | - | - | - |
| % EBITDA Margin | (2440.3%) | (2946.1%) | (642.3%) | (103.2%) | (267.5%) | (513.1%) | (551.6%) | - | - | - |
| NET Income (USD) | (1,970,046) | (3,325,598) | (3,168,617) | (2,527,245) | (5,416,509) | (10,648,525) | (12,448,386) | - | - | - |
| % Net Margin | (2408.1%) | (2994.1%) | (606.8%) | (89.4%) | (224.8%) | (442.5%) | (489.7%) | - | - | - |
Genomics plc - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.